Bibliography
- WHO Organization. Global Tuberculosis Control: Surveillance, Planning, Financing. 2007; WHO/HTM/TB/2007.376 (Geneva World Health Organization)
- Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001;123:233-8
- Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001;1:20-30
- Young D, Dye C. The development and impact of tuberculosis vaccines. Cell 2006;124:683-7
- Bifani PJ, Plikaytis BB, Kapur V, et al. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. JAMA 1996;275:452-7
- Samper S, Martin C, Pinedo A, et al. Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis. AIDS 1997;11:1237-42
- Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:479-85
- Samper S, Iglesias MJ, Rabanaque MJ, et al. Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain. J Clin Microbiol 2005;43:1220-7
- Raviglione MC, Smith IM. XDR tuberculosis – implications for global public health. N Engl J Med 2007;356:656-9
- Doggrell SA. New drugs being developed for the treatment of tuberculosis. Expert Opin Investig Drugs 2005;14:917-20
- Cardona PJ, Amat I, Gordillo S, et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005;23:1393-8
- Almond JW. Vaccine renaissance. Nat Rev Microbiol 2007;5:478-81
- Martin C. The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG? Eur Respir J 2005;26:162-7
- Martin C. Tuberculosis vaccines: past, present and future. Curr Opin Pulm Med 2006;12:186-91
- Behr MA, Small PM. Has BCG attenuated to impotence? Nature 1997;389:133-4
- Behr MA. BCG - different strains, different vaccines? Lancet Infect Dis 2002;2:86-92
- Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007;104:5596-601
- Kamath AT, Fruth U, Brennan MJ, et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 2005;23:3753-61
- Castillo-Rodal AI, Castanon-Arreola M, Hernandez-Pando R, Calva JJ, Sada-Diaz E, Lopez-Vidal Y. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infect Immun 2006;74:1718-24
- Chen JM, Islam ST, Ren H, Liu J. Differential productions of lipid virulence factors among BCG vaccine strains and implications on BCG safety. Vaccine 2007;25:8114-22
- Mahomed H, Kibel M, Hawkridge T, et al. The impact of a change in bacille Calmette-Guerin vaccine policy on tuberculosis incidence in children in Cape Town, South Africa. Pediatr Infect Dis J 2006;25:1167-72
- Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002;70:672-8
- Demangel C, Garnier T, Rosenkrands I, Cole ST. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens. Infect Immun 2005;73(4):2190-6
- Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45
- Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 2006;4:469-76
- Kaufmann SH. Is the development of a new tuberculosis vaccine possible? Nat Med 2000;6:955-60
- Mcshane H. Developing an improved vaccine against tuberculosis. Expert Rev Vaccines 2004;3:299-306
- Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996;2:893-8
- Williams A, Hatch GJ, Clark SO, et al. Evaluation of vaccines in the EU TB vaccine cluster, using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005;85:29-38
- Irwin SM, Izzo AA, Dow SW, et al. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 2005;73:5809-16
- Langermans JA, Doherty TM, Vervenne RA, et al. Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005;23:2740-50
- Reed SG, Alderson MR, Dalemans W, Lobet Y, Skeiky YA. Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb) 2003;83:213-9
- Brooks JV, Frank AA, Keen MA, Bellisle JT, Orme IM. Boosting vaccine for tuberculosis. Infect Immun 2001;69:2714-7
- Goonetilleke NP, Mcshane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 2003;171:1602-9
- Ferraz JC, Stavropoulos E, Yang M, et al. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect Immun 2004;72:6945-50
- Santosuosso M, Mccormick S, Zhang X, Zganiacz A, Xing Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 2006;74:4634-43
- Dietrich J, Billeskov R, Doherty TM, Andersen P. Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J Immunol 2007;178:3721-30
- Pelicic V, Jackson M, Reyrat JM, Jacobs WR Jr, Gicquel B, Guilhot C. Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1997;94:10955-60
- Clark-Curtiss JE, Haydel SE. Molecular genetics of Mycobacterium tuberculosis pathogenesis. Annu Rev Microbiol 2003;57:517-49
- Britton WJ, Palendira U. Improving vaccines against tuberculosis. Immunol Cell Biol 2003;81:34-45
- Ohara N, Yamada T. Recombinant BCG vaccines. Vaccine 2001;19:4089-98
- Horwitz MA. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect 2005;7:947-54
- Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000;97:13853-8
- Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun 2003;71:1672-9
- Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 2006;24:1593-600
- Pym AS, Brodin P, Majlessi L, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 2003;9:533-9
- Van Der Wel N, Hava D, Houben D, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007;129:1287-98
- Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 1998;95:5299-304
- Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 2005;115:2472-9
- Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998;393:537-44
- Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 1999;34:257-67
- Hernandez Pando R, Aguilar LD, Infante E, et al. The use of mutant mycobacteria as new vaccines to prevent tuberculosis. Tuberculosis (Edinb) 2006;86:203-10
- Smith DA, Parish T, Stoker NG, Bancroft GJ. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun 2001;69:1142-50
- Sampson SL, Dascher CC, Sambandamurthy VK, et al. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infect Immun 2004;72:3031-7
- Sambandamurthy VK, Derrick SC, Jalapathy KV, et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun 2005;73:1196-203
- Sambandamurthy VK, Derrick SC, Hsu T, et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 2006;24:6309-20
- Hinchey J, Lee S, Jeon BY, et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 2007;117:2279-88
- Rivero A, Marquez M, Santos J, et al. High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B. Clin Infect Dis 2001;32:159-61
- Samper S, Martin C. Spread of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007;13:647-8
- Andrews J, Basu S, Scales D, Maru DS, Subbaraman R. XDR-TB in South Africa: theory and practice. PLoS Med 2007;4:e163
- Soto CY, Menendez MC, Perez E, et al. IS6110 mediates increased transcription of the phoP virulence gene in a multidrug-resistant clinical isolate responsible for tuberculosis outbreaks. J Clin Microbiol 2004;42:212-9
- Haydel SE, Clark-Curtiss JE. Global expression analysis of two-component system regulator genes during Mycobacterium tuberculosis growth in human macrophages. FEMS Microbiol Lett 2004;236:341-7
- Gupta S, Sinha A, Sarkar D. Transcriptional autoregulation by Mycobacterium tuberculosis PhoP involves recognition of novel direct repeat sequences in the regulatory region of the promoter. FEBS Lett 2006;580:5328-38
- Groisman EA. The pleiotropic two-component regulatory system PhoP-PhoQ. J Bacteriol 2001;183:1835-42
- Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001;41:179-87
- Gonzalo Asensio J, Maia C, Ferrer NL, et al. The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis. J Biol Chem 2006;281:1313-6
- Cardona PJ, Soto CY, Martin C, et al. Neutral-red reaction is related to virulence and cell wall methyl-branched lipids in Mycobacterium tuberculosis. Microbes Infect 2006;8:183-90
- Saavedra R, Segura E, Tenorio EP, Lopez-Marin LM. Mycobacterial trehalose-containing glycolipid with immunomodulatory activity on human CD4+ and CD8+ T-cells. Microbes Infect 2006;8:533-40
- Saavedra R, Segura E, Leyva R, Esparza LA, Lopez-Marin LM. Mycobacterial di-O-acyl-trehalose inhibits mitogen- and antigen-induced proliferation of murine T cells in vitro. Clin Diagn Lab Immunol 2001;8:1081-8
- Walters SB, Dubnau E, Kolesnikova I, Laval F, Daffe M, Smith I. The Mycobacterium tuberculosis PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis. Mol Microbiol 2006;60:312-30
- Aguilar D, Infante E, Martin C, Gormley E, Gicquel B, Hernandez Pando R. Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain. Clin Exp Immunol 2007;147:330-8
- Martin C, Williams A, Hernandez-Pando R, et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006;24:3408-19
- Behar SM, Woodworth JS, Wu Y. Next generation: tuberculosis vaccines that elicit protective CD8+ T cells. Expert Rev Vaccines 2007;6:441-56
- Kaufmann SH. The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 2007;5:491-504
- Ehrt S, Schnappinger D, Bekiranov S, et al. Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J Exp Med 2001;194:1123-40
- Baldwin SL, D'Souza C, Roberts AD, et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 1998;66:2951-9
- Orme IM, McMurray DN, Belisle JT. Tuberculosis vaccine development: recent progress. Trends Microbiol 2001;9:115-8
- Orme IM. Preclinical testing of new vaccines for tuberculosis: a comprehensive review. Vaccine 2006;24:2-19
- Orme IM. Current progress in tuberculosis vaccine development. Vaccine 2005;23:2105-8
- Mcshane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 2004;10:1240-4
- Kaufmann SH. Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol 2006;6:699-704
- Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007;25:14-28
- Brennan MJ, Fruth U, Milstien J, Tiernan R, De Andrade Nishioka S, Chocarro L. Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med 2007;4:e252
- Stop TB Partnership – The Global Plan to Stop TB 2006 - 2015. Available at: URL: www.stoptb.org/globalplan/ [Accessed 27 December 2007]
- TB-VAC Project - A cluster for tuberculosis vaccine developments. Available at: URL: www.tb-vac.org/ [Accessed 27 December 2007]
- Aeras Global TB Vaccine Foundation homepage. Available at: URL: www.aeras.org/ [Accessed 27 December 2007]
- European and Developing Countries Clinical Trials Partnership (EDCTP) – Tuberculosis Vaccines. Available at: URL:www.edctp.org/Tuberculosis_Vaccines.232.0.html [Accessed 27 December 2007]